Cargando…

The Impact of Antipsychotic Dose Reduction on Clinical Outcomes and Health Care Resource Use Among Medicare Patients with Schizophrenia

BACKGROUND: Antipsychotic medications are used to treat schizophrenia and may be associated with adverse effects, including tardive dyskinesia (TD), following prolonged use or upon changes in dosing regimen. OBJECTIVE: This retrospective analysis evaluated the burden of antipsychotic dose reduction...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zichlin, Miriam L., Mu, Fan, Leo, Sam, Ayyagari, Rajeev
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481169/ https://www.ncbi.nlm.nih.gov/pubmed/34480726 http://dx.doi.org/10.1007/s40261-021-01060-3

Ejemplares similares

Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia
por: Caroff, Stanley N., et al.
Publicado: (2018)

Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesia
por: Caroff, Stanley N., et al.
Publicado: (2020)

Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
por: Rodolico, Alessandro, et al.
Publicado: (2022)

Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis
por: Pilon, Dominic, et al.
Publicado: (2019)

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
por: Milz, Ruth, et al.
Publicado: (2023)

Correction: Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis
por: Pilon, Dominic, et al.
Publicado: (2021)

Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
por: Bighelli, Irene, et al.
Publicado: (2022)

Racial and Ethnic Disparities in Long-Acting Injectable Antipsychotic Use in a National Sample of Medicare Beneficiaries With Schizophrenia
por: Li, Pengxiang, et al.
Publicado: (2023)

Dose Reduction/Discontinuation of Antipsychotic Drugs in Psychosis; Effect on Cognition and Functional Outcomes
por: Omachi, Yoshie, et al.
Publicado: (2018)

Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis
por: Patterson-Lomba, Oscar, et al.
Publicado: (2019)

Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia
por: Yu, Chia-Ling, et al.
Publicado: (2023)

Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction)
por: Moncrieff, Joanna, et al.
Publicado: (2019)

Correction: Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction)
Publicado: (2020)

S204. REDUCTION OF ANTIPSYCHOTIC DOSES AND POLYPHARMACY: TWO COCHRANE REVIEWS
por: Leucht, Stefan, et al.
Publicado: (2020)

Entorhinal Cortex Volume in Antipsychotic-naïve Schizophrenia
por: Jose, Sam P., et al.
Publicado: (2012)

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
por: Vogelzang, Nicholas J., et al.
Publicado: (2017)

Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States
por: Jain, Rakesh, et al.
Publicado: (2023)

Risk factors for psychotic relapse in chronic schizophrenia after dose-reduction or discontinuation of antipsychotics. A systematic review and meta-analysis
por: Bogers, J., et al.
Publicado: (2021)

Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients
por: Kamat, Siddhesh A, et al.
Publicado: (2015)

Dose-dependent effect of antipsychotic drugs on autonomic nervous system activity in schizophrenia
por: Iwamoto, Yohko, et al.
Publicado: (2012)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

The Impact of Cognitive Impairment on Resource Utilization During Medicare Home Health Care
por: Burgdorf, Julia, et al.
Publicado: (2020)

T246. RISK FACTORS FOR PSYCHOTIC RELAPSE IN CHRONIC SCHIZOPHRENIA AFTER DOSE-REDUCTION OR DISCONTINUATION OF ANTIPSYCHOTICS: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Bogers, Jan, et al.
Publicado: (2020)

Impact of Resource-Based Practice Expenses on the Medicare Physician Volume
por: Maxwell, Stephanie, et al.
Publicado: (2007)

Impact of Medicare payment policy on home health resources utilization
por: Irvine, Audrey, et al.
Publicado: (1991)

Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia
por: Kaplan, Gabriel, et al.
Publicado: (2013)

Impact of the Medicare hospital readmissions reduction program on vulnerable populations
por: Gai, Yunwei, et al.
Publicado: (2019)

Antipsychotics and risk of natural death in patients with schizophrenia
por: Chen, Yayun, et al.
Publicado: (2019)

Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation
por: Loebel, Antony, et al.
Publicado: (2015)

Correlates of high-dose antipsychotic prescription amongst outpatients with Schizophrenia in a Nigerian Hospital
por: Anozie, Ihechiluru G., et al.
Publicado: (2022)

Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2022)

Prescribing pattern of antipsychotics for patients with schizophrenia using the total daily dose online tool
por: Alsabhan, Jawza F., et al.
Publicado: (2023)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Comparative effectiveness of antipsychotic drugs in schizophrenia
por: Stroup, T. Scott, et al.
Publicado: (2000)

The heterogeneity of antipsychotic response in the treatment of schizophrenia
por: Case, M., et al.
Publicado: (2011)

New atypical antipsychotics for schizophrenia: iloperidone
por: Caccia, Silvio, et al.
Publicado: (2010)

Osteoporosis Associated with Antipsychotic Treatment in Schizophrenia
por: Wu, Haishan, et al.
Publicado: (2013)

Antipsychotic agents: efficacy and safety in schizophrenia
por: de Araújo, Arão Nogueira, et al.
Publicado: (2012)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
por: Kamei, Hiroyuki
Publicado: (2022)

O7.3. DOSE-RESPONSE META-ANALYSIS TO IDENTIFY THE OPTIMUM AND EQUIVALENT DOSES OF ANTIPSYCHOTIC DRUGS FOR SCHIZOPHRENIA
por: Leucht, Stefan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_khqbhus7ktch18i39vb4vdhj2t